Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strengthened its proprietary position in the area of protein biochip technology development and commercialization.
Zyomyx has built a United States and international patent estate that includes over 90 patents and pending patent applications. Together with rights to patents licensed by others, Zyomyx owns or has exclusive rights to more than 120 United States and international patents and patent applications. The five new patents include: U.S. Patent 6,730,516, entitled "Microfluidic Devices and Methods"; U.S. Patent 6,720,165, entitled "Methods for Making Antibody Fragments and Compositions Resulting Therefrom"; U.S. Patent 6,720,157, entitled "Chips Having Elevated Sample Surfaces"; U.S. Patent 6,186,154, entitled, "Screening of Phage Displayed Peptides without Clearing of Cell Culture"; and U.S. Patent 6,682,942, entitled, "Microdevices for Screening Biomolecules".
"The recognition by the United States Patent and Trademark Office in granting these five patents, as well as the numerous other U.S. patents that have been granted or allowed, is exciting for Zyomyx as we continue our pioneering efforts in the commercialization of protein biochip technologies in anticipation of our customers' current and future research needs," said Robert Monaghan, Zyomyx' President and Chief Executive Officer.
The Company has a strong intellectual property position in protein biochips and in other related micro-scale protein analytical methodologies. Since its founding in 1998, Zyomyx has pursued an aggressive intellectual property strategy aimed at creating substantial barriers for other companies in the protein biochip business and also at providing appropriate freedom to operate in the development and application of its core proteomics and nanofluidic technologies.